COSCIENS Biopharma Inc. has decided to voluntarily delist from Nasdaq while maintaining its listing on the TSX. The company reported Q2 2025 financial results with revenue up by 17%, gross profit up by 19%, and operating expenses reduced by 28% compared to Q2 2024. Strategic updates include a Board reconstitution, focus on revenue-generating base business, cost structure reset, and portfolio growth assessment. The Nasdaq delisting is part of a cost-saving agenda to focus resources on core business needs. Following the delisting, COSCIENS expects its common shares to trade on the OTC marketplace in the U.S. and continue trading on the TSX.

Read more at GlobeNewswire: COSCIENS Biopharma Inc. Reports Second Quarter 2025